Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
35.26
+1.17 (3.43%)
At close: Jun 26, 2026, 4:00 PM EDT
34.00
-1.26 (-3.57%)
After-hours: Jun 26, 2026, 4:37 PM EDT
Celldex Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Celldex Therapeutics stock have an average target of 55.15, with a low estimate of 38 and a high estimate of 90. The average target predicts an increase of 56.41% from the current stock price of 35.26.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Celldex Therapeutics stock from 16 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 13 | 12 | 12 | 13 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 15 | 15 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $42 | Buy | Reiterates | $42 | +19.12% | Jun 15, 2026 |
| Wolfe Research | Wolfe Research | Buy Maintains $51 → $44 | Buy | Maintains | $51 → $44 | +24.79% | Jun 15, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $44 | Buy | Maintains | $44 | +24.79% | Jun 12, 2026 |
| UBS | UBS | Buy Maintains $38 → $45 | Buy | Maintains | $38 → $45 | +27.62% | Jun 10, 2026 |
| Wells Fargo | Wells Fargo | Buy Reiterates $38 → $54 | Buy | Reiterates | $38 → $54 | +53.15% | May 13, 2026 |
Financial Forecast
Revenue This Year
2.63M
from 1.55M
Increased by 70.53%
Revenue Next Year
11.96M
from 2.63M
Increased by 354.03%
EPS This Year
-4.39
from -3.90
EPS Next Year
-4.50
from -4.39
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 9.0M | 44.5M | |
| Avg | 2.6M | 12.0M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 482.5% | 1,587.8% | |
| Avg | 70.5% | 354.0% | |
| Low | -100.0% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -4.03 | -3.78 | |
| Avg | -4.39 | -4.50 | |
| Low | -4.57 | -5.46 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.